Actualités d'Euraxi
Euraxi Pharma & AKB – A strategic partnership to improve patient access to innovation
We’re proud to announce our partnership with @AKB-medizinische Serviceleistung GmbH, a German homecare expert supporting patients with chronic and rare diseases.
🔗 This collaboration, initiated in late 2024, sets the foundation for an integrated model designed to facilitate patient access to innovative therapies :
- During clinical trials through Decentralized Home Trial Services (HTS)
- Post-marketing via dedicated Patient Support Programs (PSPs)
📍 Priority focus: the DACH region (Germany, Austria, Switzerland)
🎯 Key goals :
- Combine our expertise as a CRO and a homecare provider
- Expand geographic and demographic reach
- Reduce barriers for patients (mobility, travel constraints, pediatric needs…)
- Improve engagement and adherence with more flexible and patient-centric support
“This partnership will enable us to accelerate innovation and deliver even more effective solutions to our customers.”
— Sébastien Louveau, President of Euraxi Pharma
“Joining forces with Euraxi marks a key milestone for AKB in facilitating access to breakthrough therapies across the DACH region.”
— Peggy Matthes, CEO/Director Clinical Studies, AKB
📢 A new chapter begins—driven by shared values, complementary strengths, and a common goal: bringing research and care closer to the patients who need it most.
👉 Read the full press release here
#ClinicalTrials #HomeTrialServices #PatientCentricity #HealthcareInnovation #CRO #EuraxiPharma #AKB #DACHregion #StrategicPartnership